Estimation of Economic Consequences Linked With Different Care Management Pathways of Differentiated Thyroid Cancers

Estimation of Economic Consequences Linked With Different Care Management Pathways of Differentiated Thyroid Cancers : Involvement of Overtreatment

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03787121

Acronym

ECO-THYR

Enrollment

361

Registered

2018-12-26

Start date

2019-04-01

Completion date

2020-12-31

Last updated

2021-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid Cancer

Keywords

health economics, care management pathways, overtreatment

Brief summary

The incidence of Thyroid Cancer (TC) has increased over the last thirty years, in France and worldwide. This increase is mainly due to good prognosis microPapillary TC (mPTC). Sixty percent of diagnosed cancers are considered as over-diagnosed, leading to an over-treatment of these cases. The increase of diagnosis of mPTC and its treatment inevitably leads to an increase of medical resources consumption and corresponding costs. The primary aim of this study is to estimate the cost related to different care management pathway of TC patient during a lifetime period using a multi-state Markov model. This is a retrospective, observational population based cohort study, using data from a cohort study of TC patients implemented by the ONCOMIP network which initially aimed to perform an audit of clinical practices for the management of TC, and from database of the French social health insurance of Midi-Pyrenees region to calculate observed costs of TC management during 24 months.

Interventions

PROCEDUREcare management pathways

different care management pathways, including thyroidectomy, iode 131, hormonal treatment and type of follow up

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* all patients with a good prognosis of the TC * diagnosed in 2014 * whose medical file discussed in MultiDisciplinary Team Meeting (MDTM) in Midi-Pyrenees

Exclusion criteria

* patients whose surgical management was carried out outside Midi Pyrenees are excluded and other morphological types are excluded (medullar, anaplastic, lymphomas, sarcomas)

Design outcomes

Primary

Measure	Time frame	Description
cost related to the different management pathways of TC patient	24 months	estimate the cost related to the different management pathways of TC patient during a lifetime period using a multi-state Markov model

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026